双百口服液防治抗结核药物性肝损伤的作用机制研究  

The Preventive Effects and Mechanisms of Shuang-Bai Oral Liquid in Antituberculosis Drug-Induced Liver Injury in Rats

作　　者：唐宋琪[1] 陈云慧[2] 郑翔鸿[2] 钟森[3] 

机构地区：[1]海南医学院,海口571199 [2]成都中医药大学,成都611137 [3]成都中医药大学附属医院,成都610075

出　　处：《成都医学院学报》2014年第3期253-255,共3页Journal of Chengdu Medical College

基　　金：国家"十二五"科技重大专项(NO:2012ZX10005007);四川省支撑计划(NO:2013SZ0149)

摘　　要：目的探索双百口服液减轻抗结核化疗药物所致肝损伤的作用机制。方法采用异烟肼、利福平建立大鼠肝损伤模型。通过检测大鼠血ALT、AST,探讨双百口服液的保肝作用;通过检测大鼠肝组织CYP2E1、GSH-Px、SOD、MDA,探讨双百口服液的抗氧化作用及其对细胞色素酶CYP2E1的影响。结果双百口服液可减轻由异烟肼、利福平引起的肝脏酶学升高,降低肝组织CYP2E1、MDA含量,升高GSH-Px、SOD含量。结论双百口服液可有效控制由异烟肼、利福平引起的大鼠肝脏酶学异常升高,其作用机制可能与细胞色素酶CYP2E1及组织抗氧化酶相关。Objective To study the preventive effects and the mechanism of Shuang-bai Oral Liquid in antituberculosis drug-induced liver injury. Methods Rat liver injury model was induced by combination of isoniazid and rifampiein; hepatoprotective effect of Shuangbai Oral Liquid was investigated by detecting ALT and AST in rat blood, and antioxygenation of Shuang-bai Oral Liquid and its effect on cytoehrome enzyme CYP2E1 were studied by testing CYP2E1, GSH-Px, SOD and MDA in rat liver tissue. Results Shuang-bai Oral Liquid could inhibit the increase of AI.T and AST caused by isoniazid and rifampicin, reduce CYP2E1 and MDA content in hepatic tissue, and elevate GSH-Px and SOD content. Conclusion Shuang-bai Oral Liquid has been proved effective in inhibiting the elevated liver enzymes induced by isoniazid-rifampicin, and its protective mechanism may relate to cytochrome CYP2E1 enzyme inhibition and tissue antioxidant enzyme induction.

关 键 词：肺结核 抗痨 肝损伤 中医药 作用机制 

分 类 号：R595.3[医药卫生—内科学]